✦ LIBER ✦

P998 BENEFIT OF SORAFENIB ACCORDING TO UNDERLYING LIVER DISEASE ETIOLOGY IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA (HCC)

✍ Scribed by Bouattour, M.; Goutte, N.; Vullierme, M.-P.; Castelnau, C.; Farges, O.; Faivre, S.; Durand, F.; Castera, L.

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Efficacy and safety of sorafenib in pati

✍ Ann-Lii Cheng; Zhongzhen Guan; Zhendong Chen; Chao-Jung Tsao; Shukui Qin; Jun Su 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 553 KB

The use of single-agent sorafenib in the

✍ Joanne Chiu; Yuen Fong Tang; Tzy-Jyun Yao; Ashley Wong; Hilda Wong; Roland Leung 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 792 KB

Influence of the etiology of liver cirrh

✍ Masahiro Kanayama; Hidenari Nagai; Yasukiyo Sumino 📂 Article 📅 2008 🏛 Springer 🌐 English ⚖ 310 KB

101 INCIDENCE RATES AND RISK FACTORS ASS

✍ A.S. Lok; L.B. Seeff; T.R. Morgan; A.M. DiBisceglie; R.K. Sterling; T.M. Curto 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 53 KB

Clinical evaluation of autoantibodies to

✍ J Raedle; G Oremek; M Truschnowitsch; M Lorenz; W.K Roth; W.F Caspary; S Zeuzem 📂 Article 📅 1998 🏛 Elsevier Science 🌐 English ⚖ 122 KB

290 Cumulative Incidence and Risk Factor

✍ Ascha, Mustafa S.; Hanouneh, Ibrahim; Lopez, Rocio; Tamimi, Tarek I. Abu-Rajab; 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 80 KB